news

– Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET – Adding new clinical sites and patient dosing progressing in the AHFIRM trial CUPERTINO, Calif., May 4, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2022 and provided a corporate update. “Progress continues […]

CUPERTINO, Calif., April 27, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022. Wednesday, May 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:                               1-800-285-6670 International:                        713-481-1320

CUPERTINO, Calif., March 23, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit hosted by Kristen Kluska, Managing Director, Biotechnology Research Analyst of Cantor Fitzgerald.  The title of the panel is “Small but Mighty:

CUPERTINO, Calif., March 9, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer &

– Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET – Dosed first patient in Europe in the AHFIRM trial – Signed a licensing agreement for POSIMIR® for up to $136M CUPERTINO, Calif., March 7, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December

CUPERTINO, Calif., March 1, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients. “Dosing the first patient in Europe is an

CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022. Monday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:     

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022. Presentation details are as follows: H.C.

– DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales – Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States – DURECT to discuss agreement on Conference Call and Webcast

CUPERTINO, Calif., Dec. 14, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience. “We are delighted to welcome Peter García to our board of directors as we continue to advance our